Indication

Prostatic carcinoma

Prostatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men. Read more about Prostatic carcinoma

8 drugs 8 manufacturers

Advertisement

Drugs that treat it

Common Prostatic carcinoma therapies.

Showing 1–8 of 8 drugs

Filter & compare in the drug finder →Opens the drug finder with Prostatic carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prostatic carcinoma.

Prostatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men.

The vast majority of cases are adenocarcinomas that originate in the peripheral zone of the prostate gland and are typically driven by androgen receptor signaling.

While early-stage disease is frequently indolent and asymptomatic, progression can lead to lower urinary tract obstruction, hematuria, or metastatic dissemination predominantly to regional lymph nodes and the axial skeleton.

Pathophysiologically, it is characterized by glandular atypia, loss of basal epithelial cells, and variable histologic differentiation, which is clinically graded using the Gleason scoring system and monitored via serum prostate-specific antigen levels.

Personalize your experience

Follow Prostatic carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it